Guillain-Barre Syndrome Market Research Report - Forecast to 2027

Global Guillain-Barre Syndrome Market Research Report, by Type (AIDP, MFS, AMAN), by Diagnosis (Lumbar Puncture), by Treatment (Plasmapheresis, Medication, Physical Therapy, Hydrotherapy), and by End-User (Hospitals, Diagnostic Centers) - Global Forecast Till 2027

ID: MRFR/Pharma/4286-HCR | February 2021 | Region: Global | 90 pages

Market Scenario


Guillain-Barre Syndrome is a rare immune system disorder. In this medical condition, the patients’ immune system attacks their nervous system. The causative agents of the Guillain-Barre Syndrome are unknown. However, it is illuminated that the disease is often accompanied by infections including respiratory infection and stomach flu. The weakness of legs, difficulty in breathing, low or high blood pressure, difficulty with eye or facial movements is some of the common symptoms of the Guillain-Barre Syndrome.


The increasing prevalence of the Guillain-Barre Syndrome is expected to be one of the major drivers for the market growth during the forecast period. According to a study published by the PLOS One Journal in 2017, Guillain-Barre Syndrome is amongst some of the most common types of serious acute paralytic neuropathy. Moreover, it was estimated that about 100,000 new cases of the disease are reported, annually across the globe.


Additionally, growing geriatric population and increasing prevalence of chikungunya boost the market growth. According to the World Health Organization in 2016, about 349 936 suspected and 146,914 laboratory confirmed cases of chikungunya were reported to the PAHO regional office. Countries that reported most of the cases were Brazil (265,000 suspected cases), Bolivia, and Colombia (19,000 suspected cases). However, lack of awareness for the disease, absence of any definitive treatment, and low per capita healthcare expenditures in the middle- and low-income countries are estimated to restrain the market growth during the projected period.


Global Guillain-Barre Syndrome market is expected to grow at an approximate CAGR of 5.4% during the forecast period.


 Intended Audience



  • Pharmaceutical Companies

  • Biotechnological Institutes

  • Government and Private Laboratories

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Market Research and Consulting Service Providers


Figure 1: - Global Guillain-Barre Syndrome Market Share, By Region


 Guillain-Barre Syndrome Market


Sources: World Health Organization, PLOS One journal, Mayo Foundation for Medical Education and Research, Annual Reports, Press Release, White Paper, and Company Presentation


Segmentation


The global Guillain-Barre Syndrome market is segmented on the basis of type, diagnosis, treatment, and end-user.


On the basis of type, the market is segmented into Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP), Miller Fisher Syndrome (MFS), Acute Motor Axonal Neuropathy (AMAN), and others. On the basis of diagnosis, the market is categorized into lumbar puncture, electromyography, nerve conduction studies, and others. The electromyography segment is sub-segmented into intramuscular electromyography, surface electromyography, and others. On the basis of treatment, the market is segmented into plasmapheresis, medication, physical therapy, hydrotherapy, and others. The medication segment is sub-segmented into privigen intravenous, gammagard liquid injection, flebogamma DIF intravenous, bivigam intravenous, and others. On the basis of end-user, the market is segmented into hospitals and clinics, diagnostic centers, and others.


Research Methodology


 Guillain-Barre Syndrome Research Methodology


Sources: World Health Organization, PLOS One journal, Mayo Foundation for Medical Education and Research, Annual Reports, Press Release, White Paper, and Company Presentation


Regional Analysis


America dominates the global Guillain-Barre Syndrome market in the presence of a well-developed healthcare sector and huge patient population. Moreover, the changing lifestyle and rising per capita healthcare expenditure fuel the market. Additionally, the presence of developed economies such as the U.S. and Canada within the region fuels the market growth.


Europe stands second in the global Guillain-Barre Syndrome market. This can be attributed on the basis of availability of funds for research and a huge patient population. On a regional basis, Europe is segmented into Western Europe and Eastern Europe. Western Europe is estimated to lead the market while Eastern Europe is estimated to be the fastest growing region.


Asia Pacific is projected to be the fastest growing region for the global Guillain-Barre syndrome market due to the presence of huge patient population and developing economies such as India and China within the region. Moreover, a growing healthcare sector and the growing government support boost the regional market for the Asia Pacific region.


On the other hand, the Middle East and Africa holds the least share of the global Guillain-Barre Syndrome Market. This can be attributed to the presence of poor economies, lack of healthcare services, and stringent government policies, especially in the African region. A majority of the regions of the Middle East and Africa is held by the Middle East owing to the increasing per capita healthcare expenditure by developed economies such as Dubai, Kuwait, and Saudi Arabia within the region.


Key Players in the Global Guillain-Barre Syndrome Market


The key players in the Global Guillain-Barre Syndrome Market are Grifols (Spain), Baxter (U.S.), CSL Behring (U.S.), Akari Therapeutics Plc (U.S.), ANNEXON, INC. (U.S.), Curavac (Europe), Hansa Medical (Sweden), Vitality Biopharma (U.S.), Covidien Limited (Republic of Ireland), Natus Medical Inc. (U.S.), Electrical Geodesics Inc. (U.S.), and others.



Frequently Asked Questions (FAQ) :


Guillain-Barre Syndrome is a rare condition of the immune system where the immune system attacks the body’s own nervous system.

Guillain-Barre Syndrome Market is expected to exhibit a strong 5.4% CAGR over the forecast period till 2023.

Increasing prevalence of the disease is the major driver for the Guillain-Barre Syndrome Market.

Americas dominate the global market, followed by Europe.

Leading players in the Guillain-Barre Syndrome Market include Grifols, Baxter, and CSL Behring, among others.

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Guillain-Barre Syndrome Market, by Type

6.1 Introduction

6.2 Acute inflammatory demyelinating polyradiculoneuropathy (AIDP)

Market Estimates & Forecast, 2020–2027

6.3 Miller Fisher syndrome (MFS)

Market Estimates & Forecast, 2020–2027

6.3 Acute Motor Axonal Neuropathy (AMAN)

Market Estimates & Forecast, 2020–2027

6.4 Others

Chapter 7. Global Guillain-Barre Syndrome Market, by Diagnosis

7.1 Introduction

7.2 Lumbar Puncture

Market Estimates & Forecast, 2020–2027

7.3 Electromyography

Market Estimates & Forecast, 2020–2027

7.3.1 Intramuscular EMG

7.3.1 Surface EMG

7.4 Nerve Conduction Studies

Market Estimates & Forecast, 2020–2027

7.5 Others

Chapter 8. Global Guillain-Barre Syndrome Market, by Treatment

8.1 Introduction

8.2 Plasmapheresis

Market Estimates & Forecast, 2020–2027

8.3 Medication

Market Estimates & Forecast, 2020–2027

8.3.1 Privigen Intravenous

8.3.2 Gammagard Liquid Injection

8.3.3 Flebogamma DIF Intravenous

8.3.4 Bivigam Intravenous

8.4 Physical Therapy

Market Estimates & Forecast, 2020–2027

8.5 Hydrotherapy

Market Estimates & Forecast, 2020–2027

8.6 Others

Chapter 9. Global Guillain-Barre Syndrome Market, by End-User

9.1 Introduction

9.2 Hospitals & Clinics

Market Estimates & Forecast, 2020–2027

9.3 Diagnostic Centers

Market Estimates & Forecast, 2020–2027

9.4 Others

Chapter 10. Global Guillain-Barre Syndrome Market, by Region

10.1 Introduction

10.2 America

10.2.1 North America

10.2.1.1 U.S.

10.2.1.2 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 U.K.

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Republic of Korea

10.4.6 Rest of Asia Pacific

10.5 Middle East & Africa

10.5.1 United Arab Emirates

10.5.2 Saudi Arabia

10.5.3 Oman

10.5.4 Kuwait

10.5.5 Qatar

10.5.6 Rest of the Middle East & Africa

Chapter 11. Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

11.3.1 Key Developments

Chapter 12 Company Profiles

12.1 Grifols

12.1.1 Company Overview

12.1.2 Type Overview

12.1.3 Financials

12.2.4 Key Developments

12.1.5 SWOT Analysis

12.2 Baxter

12.2.1 Company Overview

12.2.2 Type Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 CSL Behring

12.3.1 Company Overview

12.3.2 Type Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 Akari Therapeutics Plc

12.4.1 Company Overview

12.4.2 Type/Business Segment Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 ANNEXON, INC.

12.5.1 Company Overview

12.5.2 Type Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.5.5 SWOT Analysis

12.6 Curavac

12.6.1 Company Overview

12.6.2 Type Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.6.5 SWOT Analysis

12.7 Hansa Medical

12.7.1 Overview

12.7.2 Type Overview

12.7.3 Financials

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 Vitality Biopharma

12.8.1 Overview

12.8.2 Type Overview

12.8.3 Financials

12.8.4 Key Developments

12.8.5 SWOT Analysis

12.9 Covidien Limited

12.9.1 Overview

12.9.2 Type Overview

12.9.3 Financials

12.9.4 Key Developments

12.9.5 SWOT Analysis

12.10 Natus Medical Inc.

12.10.1 Overview

12.10.2 Type Overview

12.10.3 Financials

12.10.4 Key Developments

12.10.5 SWOT Analysis

12.11 Electrical Geodesics Inc.

12.11.1 Overview

12.11.2 Type Overview

12.11.3 Financials

12.11.4 Key Developments

12.11.5 SWOT Analysis

12.12 Others

Chapter 13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Prediction of Guillain-Barre Syndrome Market

Chapter 14 Appendix

LIST OF TABLES

Table 1 Guillain-Barre Syndrome Industry Synopsis, 2020–2027

Table 2 Global Guillain-Barre Syndrome Market Estimates & Forecast, 2020–2027, (USD Million)

Table 3 Global Guillain-Barre Syndrome Market, by Region, 2020–2027, (USD Million)

Table 4 Global Guillain-Barre Syndrome Market, by Type, 2020–2027, (USD Million)

Table 5 Global Guillain-Barre Syndrome Market, by Diagnosis, 2020–2027, (USD Million)

Table 6 Global Guillain-Barre Syndrome Market, by Treatment, 2020–2027, (USD Million)

Table 7 Global Guillain-Barre Syndrome Market, by End-User, 2020–2027, (USD Million

Table 8 North America Guillain-Barre Syndrome Market, by Type, 2020–2027, (USD Million)

Table 9 North America Guillain-Barre Syndrome, by Diagnosis, 2020–2027, (USD Million)

Table 10 North America Guillain-Barre Syndrome, by Treatment, 2020–2027, (USD Million)

Table 11 North America Guillain-Barre Syndrome, by End-User, 2020–2027, (USD Million)

Table 12 U.S. Guillain-Barre Syndrome Market, by Type, 2020–2027, (USD Million)

Table 13 U.S. Guillain-Barre Syndrome Market, by Diagnosis, 2020–2027, (USD Million)

Table 14 U.S. Guillain-Barre Syndrome Market, by Treatment, 2020–2027, (USD Million)

Table 15 U.S. Guillain-Barre Syndrome Market, by End-User, 2020–2027, (USD Million)

Table 16 Canada Guillain-Barre Syndrome Market, by Type, 2020–2027, (USD Million)

Table 17 Canada Guillain-Barre Syndrome Market, by Diagnosis, 2020–2027, (USD Million)

Table 18 Canada Guillain-Barre Syndrome Market, by Treatment, 2020–2027, (USD Million)

Table 19 Canada Guillain-Barre Syndrome Market, by End-User, 2020–2027, (USD Million)

Table 20 South America Guillain-Barre Syndrome Market, by Type, 2020–2027, (USD Million)

Table 21 South America Guillain-Barre Syndrome Market, by Diagnosis, 2020–2027, (USD Million)

Table 22 South America Guillain-Barre Syndrome Market, by Treatment, 2020–2027, (USD Million)

Table 23 South America Guillain-Barre Syndrome Market, by End-User, 2020–2027, (USD Million)

Table 24 Europe Guillain-Barre Syndrome Market, by Type, 2020–2027, (USD Million)

Table 25 Europe Guillain-Barre Syndrome Market, by Diagnosis, 2020–2027, (USD Million)

Table 26 Europe Guillain-Barre Syndrome Market, by Treatment, 2020–2027, (USD Million)

Table 27 Europe Guillain-Barre Syndrome Market, by End-User, 2020–2027, (USD Million)

Table 28 Western Europe Guillain-Barre Syndrome Market, by Type, 2020–2027, (USD Million)

Table 29 Western Europe Guillain-Barre Syndrome Market, by Diagnosis, 2020–2027, (USD Million)

Table 30 Western Europe Guillain-Barre Syndrome Market, by Treatment, 2020–2027, (USD Million)

Table 31 Western Europe Guillain-Barre Syndrome Market, by End-User, 2020–2027, (USD Million)

Table 32 Eastern Europe Guillain-Barre Syndrome Market, by Type, 2020–2027, (USD Million)

Table 33 Eastern Europe Guillain-Barre Syndrome Market, by Diagnosis, 2020–2027, (USD Million)

Table 34 Eastern Europe Guillain-Barre Syndrome Market, by Treatment, 2020–2027, (USD Million)

Table 35 Eastern Europe Guillain-Barre Syndrome Market, by End-User, 2020–2027, (USD Million)

Table 36 Asia Pacific Guillain-Barre Syndrome Market, by Type, 2020–2027, (USD Million)

Table 37 Asia Pacific Guillain-Barre Syndrome Market, by Diagnosis, 2020–2027, (USD Million)

Table 38 Asia Pacific Guillain-Barre Syndrome Market, by Treatment, 2020–2027, (USD Million)

Table 39 Asia Pacific Guillain-Barre Syndrome Market, by End-User, 2020–2027, (USD Million)

Table 40 Middle East & Africa Guillain-Barre Syndrome Market, by Type, 2020–2027, (USD Million)

Table 41 Middle East & Africa Guillain-Barre Syndrome Market, by Diagnosis, 2020–2027, (USD Million)

Table 42 Middle East & Africa Guillain-Barre Syndrome Market, by Treatment, 2020–2027, (USD Million)

Table 43 Middle East & Africa Guillain-Barre Syndrome Market, by End-User, 2020–2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Guillain-Barre Syndrome Market

Figure 3 Market Dynamics for Global Guillain-Barre Syndrome Market

Figure 4 Global Guillain-Barre Syndrome Market Share, by Type 2020

Figure 5 Global Guillain-Barre Syndrome Market Share, by Diagnosis 2020

Figure 6 Global Guillain-Barre Syndrome Market Share, by Treatment, 2020

Figure 7 Global Guillain-Barre Syndrome Market Share, by End-User, 2020

Figure 8 Global Guillain-Barre Syndrome Market Share, by Region, 2020

Figure 9 North America Guillain-Barre Syndrome Market Share, by Country, 2020

Figure 10 Europe Guillain-Barre Syndrome Market Share, by Country, 2020

Figure 11 Asia Pacific Guillain-Barre Syndrome Market Share, by Country, 2020

Figure 12 The Middle East & Africa Guillain-Barre Syndrome Market Share, by Country, 2020

Figure 13 Global Guillain-Barre Syndrome Market: Company Share Analysis, 2020 (%)

Figure 14 Grifols: Key Financials

Figure 15 Grifols: Segmental Revenue

Figure 16 Grifols: Geographical Revenue

Figure 17 Baxter: Key Financials

Figure 18 Baxter: Segmental Revenue

Figure 19 Baxter: Geographical Revenue

Figure 20 CSL Behring: Key Financials

Figure 21 CSL Behring: Segmental Revenue

Figure 22 CSL Behring: Geographical Revenue

Figure 23 Akari Therapeutics Plc: Key Financials

Figure 24 Akari Therapeutics Plc: Segmental Revenue

Figure 25 Akari Therapeutics Plc: Geographical Revenue

Figure 26 ANNEXON, INC.: Key Financials

Figure 27 ANNEXON, INC.: Segmental Revenue

Figure 28 ANNEXON, INC.: Geographical Revenue

Figure 29 Curavac: Key Financials

Figure 30 Curavac: Segmental Revenue

Figure 31 Curavac: Geographical Revenue

Figure 32 Hansa Medical: Key Financials

Figure 33 Hansa Medical: Segmental Revenue

Figure 34 Hansa Medical: Geographical Revenue

Figure 35 Vitality Biopharma: Key Financials

Figure 36 Vitality Biopharma: Segmental Revenue

Figure 37 Vitality Biopharma: Geographical Revenue

Figure 38 Covidien Limited: Key Financials

Figure 39 Covidien Limited: Segmental Revenue

Figure 40 Covidien Limited: Geographical Revenue

Figure 41 Natus Medical Inc.: Key Financials

Figure 42 Natus Medical Inc.: Segmental Revenue

Figure 43 Natus Medical Inc.: Geographical Revenue

Figure 41 Electrical Geodesics Inc.: Key Financials

Figure 42 Electrical Geodesics Inc.: Segmental Revenue

Figure 43 Electrical Geodesics Inc.: Geographical Revenue